Literature DB >> 33446512

Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset.

Varun Sasisekharan1, Niharika Pentakota1, Akila Jayaraman1, Kannan Tharakaraman1, Gerald N Wogan2,3, Uma Narayanasami4.   

Abstract

Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection during the current pandemic remains a field of immense interest and active research worldwide. Although the severity of acute infection may depend on the intensity of innate and adaptive immunity, leading to higher morbidity and mortality, the longevity of IgG antibodies, including neutralizing activity to SARS-CoV-2, is viewed as a key correlate of immune protection. Amid reports and concern that there is a rapid decay of IgG antibody levels within 1 mo to 2 mo after acute infection, we set out to study the pattern and duration of IgG antibody response to various SARS-CoV-2 antigens in asymptomatic and symptomatic patients in a community setting. Herein, we show the correlation of IgG anti-spike protein S1 subunit, receptor binding domain, nucleocapsid, and virus neutralizing antibody titers with each other and with clinical features such as length and severity of COVID-19 illness. More importantly, using orthogonal measurements, we found the IgG titers to persist for more than 4 mo post symptom onset, implying that long-lasting immunity to COVID-19 from infection or vaccination might be observed, as seen with other coronaviruses such as SARS and Middle East respiratory syndrome.
Copyright © 2021 the Author(s). Published by PNAS.

Entities:  

Keywords:  SARS-CoV-2; antigens; immunity; orthogonal

Mesh:

Substances:

Year:  2021        PMID: 33446512      PMCID: PMC7865175          DOI: 10.1073/pnas.2021615118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  42 in total

1.  Human neutralizing antibodies elicited by SARS-CoV-2 infection.

Authors:  Bin Ju; Qi Zhang; Jiwan Ge; Ruoke Wang; Jing Sun; Xiangyang Ge; Jiazhen Yu; Sisi Shan; Bing Zhou; Shuo Song; Xian Tang; Jinfang Yu; Jun Lan; Jing Yuan; Haiyan Wang; Juanjuan Zhao; Shuye Zhang; Youchun Wang; Xuanling Shi; Lei Liu; Jincun Zhao; Xinquan Wang; Zheng Zhang; Linqi Zhang
Journal:  Nature       Date:  2020-05-26       Impact factor: 49.962

2.  Loss of Anti-SARS-CoV-2 Antibodies in Mild Covid-19.

Authors:  Edwin Bölke; Christiane Matuschek; Johannes C Fischer
Journal:  N Engl J Med       Date:  2020-09-23       Impact factor: 91.245

3.  Human-IgG-Neutralizing Monoclonal Antibodies Block the SARS-CoV-2 Infection.

Authors:  Jinkai Wan; Shenghui Xing; Longfei Ding; Yongheng Wang; Chenjian Gu; Yanling Wu; Bowen Rong; Cheng Li; Siqing Wang; Kun Chen; Chenxi He; Dandan Zhu; Songhua Yuan; Chengli Qiu; Chen Zhao; Lei Nie; Zhangzhao Gao; Jingyu Jiao; Xiaoyan Zhang; Xiangxi Wang; Tianlei Ying; Haibin Wang; Youhua Xie; Yanan Lu; Jianqing Xu; Fei Lan
Journal:  Cell Rep       Date:  2020-07-03       Impact factor: 9.423

Review 4.  A systematic review of asymptomatic infections with COVID-19.

Authors:  Zhiru Gao; Yinghui Xu; Chao Sun; Xu Wang; Ye Guo; Shi Qiu; Kewei Ma
Journal:  J Microbiol Immunol Infect       Date:  2020-05-15       Impact factor: 4.399

5.  Convergent antibody responses to SARS-CoV-2 in convalescent individuals.

Authors:  Davide F Robbiani; Christian Gaebler; Frauke Muecksch; Julio C C Lorenzi; Zijun Wang; Alice Cho; Marianna Agudelo; Christopher O Barnes; Anna Gazumyan; Shlomo Finkin; Thomas Hägglöf; Thiago Y Oliveira; Charlotte Viant; Arlene Hurley; Hans-Heinrich Hoffmann; Katrina G Millard; Rhonda G Kost; Melissa Cipolla; Kristie Gordon; Filippo Bianchini; Spencer T Chen; Victor Ramos; Roshni Patel; Juan Dizon; Irina Shimeliovich; Pilar Mendoza; Harald Hartweger; Lilian Nogueira; Maggi Pack; Jill Horowitz; Fabian Schmidt; Yiska Weisblum; Eleftherios Michailidis; Alison W Ashbrook; Eric Waltari; John E Pak; Kathryn E Huey-Tubman; Nicholas Koranda; Pauline R Hoffman; Anthony P West; Charles M Rice; Theodora Hatziioannou; Pamela J Bjorkman; Paul D Bieniasz; Marina Caskey; Michel C Nussenzweig
Journal:  Nature       Date:  2020-06-18       Impact factor: 69.504

6.  Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability.

Authors:  Philip J M Brouwer; Tom G Caniels; Karlijn van der Straten; Jonne L Snitselaar; Yoann Aldon; Sandhya Bangaru; Jonathan L Torres; Nisreen M A Okba; Mathieu Claireaux; Gius Kerster; Arthur E H Bentlage; Marlies M van Haaren; Denise Guerra; Judith A Burger; Edith E Schermer; Kirsten D Verheul; Niels van der Velde; Alex van der Kooi; Jelle van Schooten; Mariëlle J van Breemen; Tom P L Bijl; Kwinten Sliepen; Aafke Aartse; Ronald Derking; Ilja Bontjer; Neeltje A Kootstra; W Joost Wiersinga; Gestur Vidarsson; Bart L Haagmans; Andrew B Ward; Godelieve J de Bree; Rogier W Sanders; Marit J van Gils
Journal:  Science       Date:  2020-06-15       Impact factor: 47.728

Review 7.  Coronaviruses and SARS-CoV-2: A Brief Overview.

Authors:  Stephan Ludwig; Alexander Zarbock
Journal:  Anesth Analg       Date:  2020-07       Impact factor: 5.108

8.  Humoral Immune Response to SARS-CoV-2 in Iceland.

Authors:  Daniel F Gudbjartsson; Gudmundur L Norddahl; Pall Melsted; Kristbjorg Gunnarsdottir; Hilma Holm; Elias Eythorsson; Asgeir O Arnthorsson; Dadi Helgason; Kristbjorg Bjarnadottir; Ragnar F Ingvarsson; Brynja Thorsteinsdottir; Steinunn Kristjansdottir; Kolbrun Birgisdottir; Anna M Kristinsdottir; Martin I Sigurdsson; Gudny A Arnadottir; Erna V Ivarsdottir; Margret Andresdottir; Frosti Jonsson; Arna B Agustsdottir; Jonas Berglund; Berglind Eiriksdottir; Run Fridriksdottir; Elisabet E Gardarsdottir; Magnus Gottfredsson; Olafia S Gretarsdottir; Steinunn Gudmundsdottir; Kjartan R Gudmundsson; Thora R Gunnarsdottir; Arnaldur Gylfason; Agnar Helgason; Brynjar O Jensson; Aslaug Jonasdottir; Hakon Jonsson; Thordur Kristjansson; Karl G Kristinsson; Droplaug N Magnusdottir; Olafur T Magnusson; Lovisa B Olafsdottir; Solvi Rognvaldsson; Louise le Roux; Gudrun Sigmundsdottir; Asgeir Sigurdsson; Gardar Sveinbjornsson; Kristin E Sveinsdottir; Maney Sveinsdottir; Emil A Thorarensen; Bjarni Thorbjornsson; Marianna Thordardottir; Jona Saemundsdottir; S Hjortur Kristjansson; Kamilla S Josefsdottir; Gisli Masson; Gudmundur Georgsson; Mar Kristjansson; Alma Moller; Runolfur Palsson; Thorolfur Gudnason; Unnur Thorsteinsdottir; Ingileif Jonsdottir; Patrick Sulem; Kari Stefansson
Journal:  N Engl J Med       Date:  2020-09-01       Impact factor: 91.245

9.  Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19.

Authors:  Xiangyu Chen; Zhiwei Pan; Shuai Yue; Fei Yu; Junsong Zhang; Yang Yang; Ren Li; Bingfeng Liu; Xiaofan Yang; Leiqiong Gao; Zhirong Li; Yao Lin; Qizhao Huang; Lifan Xu; Jianfang Tang; Li Hu; Jing Zhao; Pinghuang Liu; Guozhong Zhang; Yaokai Chen; Kai Deng; Lilin Ye
Journal:  Signal Transduct Target Ther       Date:  2020-09-02

10.  Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans.

Authors:  Alessandro Sette; Daniela Weiskopf; Jose Mateus; Alba Grifoni; Alison Tarke; John Sidney; Sydney I Ramirez; Jennifer M Dan; Zoe C Burger; Stephen A Rawlings; Davey M Smith; Elizabeth Phillips; Simon Mallal; Marshall Lammers; Paul Rubiro; Lorenzo Quiambao; Aaron Sutherland; Esther Dawen Yu; Ricardo da Silva Antunes; Jason Greenbaum; April Frazier; Alena J Markmann; Lakshmanane Premkumar; Aravinda de Silva; Bjoern Peters; Shane Crotty
Journal:  Science       Date:  2020-08-04       Impact factor: 47.728

View more
  10 in total

1.  Evolution of antibodies against SARS-CoV-2 over seven months: Experience of the nationwide seroprevalence ENE-COVID study in Spain.

Authors:  Mayte Pérez-Olmeda; José María Saugar; Aurora Fernández-García; Beatriz Pérez-Gómez; Marina Pollán; Ana Avellón; Roberto Pastor-Barriuso; Nerea Fernández-de Larrea; Mariano Martín; Israel Cruz; Jose L Sanmartín; Giovanni Fedele; Jose León Paniagua; Juan F Muñoz-Montalvo; Faustino Blanco; Raquel Yotti; Jesús Oteo-Iglesias
Journal:  J Clin Virol       Date:  2022-03-11       Impact factor: 14.481

2.  Strong Cellular Immune Response, but Not Humoral, against SARS-CoV-2 in Oncohematological Patients with Autologous Stem Cell Transplantation after Natural Infection.

Authors:  Lorena Vigón; Adrián Sánchez-Tornero; Sara Rodríguez-Mora; Javier García-Pérez; Magdalena Corona de Lapuerta; Lucía Pérez-Lamas; Guiomar Casado-Fernández; Gemma Moreno; Montserrat Torres; Elena Mateos; María Aránzazu Murciano-Antón; José Alcamí; Mayte Pérez-Olmeda; Javier López-Jiménez; Valentín García-Gutiérrez; Mayte Coiras
Journal:  J Clin Med       Date:  2022-04-11       Impact factor: 4.964

3.  Development of a Colloidal Gold-Based Immunochromatographic Strip for Rapid Detection of Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein.

Authors:  Ge Li; Aiping Wang; Yumei Chen; Yaning Sun; Yongkun Du; Xun Wang; Peiyang Ding; Rui Jia; Yanwei Wang; Gaiping Zhang
Journal:  Front Immunol       Date:  2021-03-11       Impact factor: 7.561

4.  Antibody screening at reduced pH enables preferential selection of potently neutralizing antibodies targeting SARS-CoV-2.

Authors:  Bharat Madan; Eswar R Reddem; Pengfei Wang; Ryan G Casner; Manoj S Nair; Yaoxing Huang; Ahmed S Fahad; Matheus Oliveira de Souza; Bailey B Banach; Sheila N López Acevedo; Xiaoli Pan; Rajani Nimrania; I-Ting Teng; Fabiana Bahna; Tongqing Zhou; Baoshan Zhang; Michael T Yin; David D Ho; Peter D Kwong; Lawrence Shapiro; Brandon J DeKosky
Journal:  AIChE J       Date:  2021-10-04       Impact factor: 3.993

5.  Performance verification of the Abbott SARS-CoV-2 test for qualitative detection of IgG in Cali, Colombia.

Authors:  Maria Del Mar Castro; Isabella Caicedo; Helen Johanna Ortiz-Rojas; Carmen Manuela Castillo; Adriana Giovanna Medina; Neal Alexander; Maria Adelaida Gómez; Ludwig L Albornoz
Journal:  PLoS One       Date:  2021-09-01       Impact factor: 3.240

6.  Simultaneous Measurement of IgM and IgG Antibodies to SARS-CoV-2 Spike, RBD, and Nucleocapsid Multiplexed in a Single Assay on the xMAP INTELLIFLEX DR-SE Flow Analyzer.

Authors:  Andrew Cameron; Jessica L Bohrhunter; Claire A Porterfield; Rupinder Mangat; Michael H Karasick; Zachary Pearson; Stephen Angeloni; Nicole D Pecora
Journal:  Microbiol Spectr       Date:  2022-04-07

7.  Longitudinal assessment of anti-SARS-CoV-2 antibody dynamics and clinical features following convalescent from COVID-19 infection.

Authors:  Catharina Gerhards; Margot Thiaucourt; Maximilian Kittel; Celine Becker; Volker Ast; Michael Hetjens; Michael Neumaier; Verena Haselmann
Journal:  Int J Infect Dis       Date:  2021-04-28       Impact factor: 3.623

8.  SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response.

Authors:  Ourania E Tsitsilonis; Dimitrios Paraskevis; Evi Lianidou; Evangelos Terpos; Athanasios Akalestos; Vassilios Pierros; Evangelia Georgia Kostaki; Efstathios Kastritis; Paraskevi Moutsatsou; Marianna Politou; Andreas Scorilas; Thomas Sphicopoulos; Nikolaos Thomaidis; Ioannis P Trougakos; Athanassios Tsakris; Nikolaos Voulgaris; Christina C Daskalaki; Zoi Evangelakou; Christina Fouki; Despoina D Gianniou; Sentiljana Gumeni; Ioannis V Kostopoulos; Maria S Manola; Nikolaos Orologas-Stavrou; Chrysanthi Panteli; Eleni-Dimitra Papanagnou; Pantelis Rousakis; Aimilia D Sklirou; Stavroula Smilkou; Dimitra Stergiopoulou; Sotirios Tsiodras; Meletios-Athanasios Dimopoulos; Petros P Sfikakis
Journal:  Vaccines (Basel)       Date:  2021-03-02

9.  Persistence of humoral response upon SARS-CoV-2 infection.

Authors:  Andrea Knies; Dennis Ladage; Ralf J Braun; Janine Kimpel; Miriam Schneider
Journal:  Rev Med Virol       Date:  2021-06-30       Impact factor: 11.043

10.  The seroprevalence of COVID-19 in patients living with HIV in metropolitan Detroit.

Authors:  Smitha Gudipati; Monica Lee; Megan Scott; Sean Yaphe; Joanne Huisting; Nicholas Yared; Indira Brar; Norman Markowitz
Journal:  Int J STD AIDS       Date:  2022-03-25       Impact factor: 1.456

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.